SUNOSI (Solariamfetol), Drug Insight and Market Forecast - 2032

“SUNOSI (Solariamfetol), Drug Insight and Market Forecast - 2032” report provides comprehensive insights about SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS) in the 7MM. A detailed picture of the SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the SUNOSI ( Solariamfetol) for Excessive Daytime Sleepiness (EDS) . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SUNOSI (Solariamfetol) market forecast, analysis for Excessive Daytime Sleepiness (EDS) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Excessive Daytime Sleepiness (EDS).

Drug Summary

SUNOSI is a dual-acting Dopamine, and Norepinephrine Reuptake Inhibitor (DNRI) is indicated to improve wakefulness in adults living with Excessive Daytime Sleepiness (EDS) due to narcolepsy or OSA. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize SUNOSI from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to SUNOSI, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China, and Japan. SUNOSI received an Orphan Drug designation for narcolepsy in the United States.

Dosage

• The drug is administered once daily upon awakening. It is recommended to avoid administration within 9 hours of planned bedtime because of the potential to interfere with sleep.
• Starting dose for patients with narcolepsy: 75 mg once daily.
• Starting dose for patients with OSA: 37.5 mg once daily.
• The dose may be increased at intervals of at least 3 days.
• The maximum dose is 150 mg once daily.

Mechanism of Action
The mechanism of action of Solriamfetol to improve wakefulness in patients with EDS associated with narcolepsy or OSA is unclear. However, its efficacy could be mediated through its activity as a Dopamine and Norepinephrine Reuptake Inhibitor (DNRI).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SUNOSI (Solariamfetol) description, mechanism of action, dosage and administration, research and development activities in Excessive Daytime Sleepiness (EDS).
• Elaborated details on SUNOSI (Solariamfetol) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SUNOSI (Solariamfetol) research and development activity in Excessive Daytime Sleepiness (EDS) in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SUNOSI (Solariamfetol).
• The report contains forecasted sales of SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Excessive Daytime Sleepiness (EDS).
• The report also features the SWOT analysis with analyst views for SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SUNOSI (Solariamfetol) Analytical Perspective

In-depth SUNOSI ( Solariamfetol) Market Assessment

This report provides a detailed market assessment of SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

SUNOSI ( Solariamfetol) Clinical Assessment

The report provides the clinical trials information of SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Excessive Daytime Sleepiness (EDS) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SUNOSI (Solariamfetol) dominance.
• Other emerging products for Excessive Daytime Sleepiness (EDS) are expected to give tough market competition to SUNOSI (Solariamfetol) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS).
• Our in-depth analysis of the forecasted sales data of SUNOSI (Solariamfetol) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS).

Key Questions Answered

• What is the product type, route of administration and mechanism of action of SUNOSI (Solariamfetol)?
• What is the clinical trial status of the study related to SUNOSI (Solariamfetol) in Excessive Daytime Sleepiness (EDS) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SUNOSI (Solariamfetol) development?
• What are the key designations that have been granted to SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS)?
• What is the forecasted market scenario of SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS)?
• What are the forecasted sales of SUNOSI (Solariamfetol) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Excessive Daytime Sleepiness (EDS) and how are they giving competition to SUNOSI (Solariamfetol) for Excessive Daytime Sleepiness (EDS)?
• Which are the late-stage emerging therapies under development for the treatment of Excessive Daytime Sleepiness (EDS)?